4.7 Article

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab

期刊

出版社

MDPI
DOI: 10.3390/ijms241210379

关键词

adalimumab; infliximab; antidrug antibodies; therapeutic drug monitoring; immunoassays comparison

向作者/读者索取更多资源

Therapeutic drug monitoring (TDM) is important for the treatment of inflammatory diseases. In this study, we evaluated the performance of different assays for drug and antidrug antibodies (ADA) measurement. The results showed that the four immunoassays (Promonitor, i-Track10®, ez-Track1, and Lisa Tracker® ELISA) performed well in drug and ADA measurement.
Therapeutic drug monitoring (TDM) of anti-TNF-& alpha; is an important tool in clinical practice for inflammatory diseases. In this study, we have evaluated the performance of several assays for drug and antidrug antibodies (ADA) measurement in the serum. 50 sera from patients treated with infliximab (IFX) and 49 sera from patients treated with adalimumab (ADAL) were monitored with four immunoassays. We have compared Promonitor, i-Track10(& REG;), and ez-track1 assays to our gold standard Lisa Tracker(& REG;) ELISA using Cohen's kappa, Passing-Bablok, and Bland-Altman analysis. The qualitative analysis evaluated by Cohen's kappa values found for IFX measurements an almost perfect concordance for Promonitor, moderate for i-Track10(& REG;) and substantial for ez-Track1. For ADAL, kappa values were moderate for all tested methods. For anti-IFX, kappa values were almost perfect for Promonitor, fair for i-Track10(& REG;), and substantial for ez-Track1. For anti-ADAL, kappa values were almost perfect for all three assays. For quantitative analysis of drug measurements, Pearson's r values were all above 0.9 and Lin's concordance coefficients of all immunoassays were around 0.80. Performances of the four evaluated immunoassays were acceptable for TDM based on our laboratory experience. Nevertheless, concordance between the four methods for IFX measurement was not perfect and we recommend the use of the same assay for the follow-up of a given patient. The performances of the four immunoassays evaluated were similar and are acceptable for TDM based on our laboratory experience.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据